ARKG ARK Genomic Revolution ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Tempus AI, Inc., 2.76M shares ($175M).
| Current positions Top 10 | % of book |
|---|---|
| Tempus AI, Inc. TEM $175M | 9.6% |
| Twist Bioscience Corporation TWST $155M | 8.5% |
| 10x Genomics, Inc. TXG $140M | 7.7% |
| CRISPR Therapeutics AG CRSP $95.4M | 5.2% |
| Guardant Health, Inc. GH $93.4M | 5.1% |
| Eli Lilly and Company LLY $91.6M | 5.0% |
| Illumina, Inc. ILMN $85.0M | 4.7% |
| Absci Corporation ABSI $82.5M | 4.5% |
| Natera, Inc. NTRA $81.5M | 4.5% |
| CareDx, Inc. CDNA $67.6M | 3.7% |
Slices are % of holdings value.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 98.6% |
| Technology | 1.1% |
| Unclassified | 0.3% |
| Industries | % of holdings value |
|---|---|
| Biotechnology | 49.4% |
| Diagnostics & Research | 26.1% |
| Health Information Services | 9.6% |
| Medical Devices | 8.5% |
| Drug Manufacturers - General | 5.0% |
| Scientific & Technical Instruments | 1.1% |
| Unclassified | 0.3% |
Source: the fund's own published holdings, the portfolio of Nov 18, 2026 (assets.ark-funds.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Nov 28, 2025.
The ARK Genomic Revolution ETF's ("Fund") investment objective is long-term growth of capital.
Principal investment strategies
The Fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Fund's investment theme of the genomics* revolution ("Genomics Revolution Companies"), which is described below: • Genomic Revolution Companies. Companies that the Adviser believes are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business, such as by offering new products or services that rely on genomic sequencing,** analysis, synthesis or instrumentation. These companies may include ones across multiple sectors, such as healthcare, information technology, materials, energy and consumer discretionary. These companies may also develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics,*** molecular medicine and agricultural biotechnology. In selecting companies that the Adviser believes are relevant to a particular investment theme, the Adviser seeks to identify, using its own internal research and analysis, companies capitalizing on disruptive innovation or that are enabling the further development of a theme in the markets in which they operate. The Adviser's internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment themes and identify and take advantage of trends that have ramifications for individual companies or entire industries. The Adviser's process for identifying Genomic Revolution Companies uses both "top down" (thematic research sizing the potential total available market, and surfacing the prime beneficiaries) and "bottom up" (valuation, fundamental and quantitative measures) approaches. In both the Adviser's "top down" and "bottom up" approaches, the Adviser evaluates environmental, social, and governance ("ESG") considerations. In its "top down" approach, the Adviser uses the framework of the United Nations Sustainable Development Goals to integrate ESG considerations into its research and investment process. The Adviser, however, does not use ESG considerations to limit, restrict or otherwise exclude companies or sectors from the Fund's investment universe. In its "bottom up" approach, the Adviser makes its investment decisions primarily based on its analysis of the potential of individual companies, while integrating ESG considerations into that process. The Adviser's highest-conviction investment ideas are those that it believes present the best risk-reward opportunities. The Fund may invest in certain companies that the Adviser believes are well-positioned to capitalize on and expected to devote substantial efforts to business lines enabled by disruptive genomic innovation, even if such companies do not currently derive a substantial portion of their revenues from genomics related activities. Under normal circumstances, substantially all of the Fund's assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Fund's investments will include micro-, small-, medium- and large-capitalization companies. The Fund's investments in foreign equity securities will be in both developed and emerging markets. _______________ * The Adviser defines "genomics" as the study of genes and their functions, and related techniques (e.g., genomic sequencing).
Management and Contact
- Adviser
- ARK Investment Management LLC
- Portfolio managers
-
The following individual has been primarily responsible for the day-to-day management of the Fund's portfolio since the inception of the Fund: Catherine D. Wood.
- Phone
- 855-406-1506
- [email protected]
Track Record as of Dec 31, 2024
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | 5 Years | 10 Years | |
|---|---|---|---|
| Returns Before Taxes | -28.09% | -6.52% | 1.90% |
| Returns After Taxes on Distributions(1) | -28.09% | -6.60% | 1.62% |
| Returns After Taxes on Distributions and Sale of Fund Shares(1) | -16.63% | -4.72% | 1.46% |
| MSCI World Index (reflects no deduction for fees, expenses or taxes) | 18.67% | 11.17% | 9.95% |
| NASDAQ Healthcare Index (reflects no deduction for fees, expenses or taxes) | -0.86% | 1.06% | 3.19% |
| S&P 500 Index (reflects no deduction for fees, expenses or taxes) | 25.02% | 14.53% | 13.10% |
Holdings as of Nov 18, 2026
The full portfolio the fund publishes every business day on its website (assets.ark-funds.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 17, 2026.
34 lines, 33 linked, weights sum to 99.99% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| TEMPUS AI INC-CL A | TEM 88023B103 | Equity | 2,761,952 | −39,975 | 9.63% | $ 175.191M |
| TWIST BIOSCIENCE CORP | TWST 90184D100 | Equity | 1,381,558 | +11,337 | 8.50% | $ 154.734M |
| 10X GENOMICS INC-CLASS A | TXG 88025U109 | Equity | 2,480,914 | −145,124 | 7.68% | $ 139.675M |
| CRISPR THERAPEUTICS AG | CRSP H17182108 | Equity | 2,376,723 | 0 | 5.24% | $ 95.425M |
| GUARDANT HEALTH INC | GH 40131M109 | Equity | 651,785 | −9,425 | 5.13% | $ 93.388M |
| ELI LILLY & CO | LLY 532457108 | Equity | 64,741 | −936 | 5.04% | $ 91.644M |
| ILLUMINA INC | ILMN 452327109 | Equity | 419,496 | −6,071 | 4.67% | $ 84.994M |
| ABSCI CORP | ABSI 00091E109 | Equity | 10,883,235 | −157,547 | 4.53% | $ 82.495M |
| NATERA INC | NTRA 632307104 | Equity | 283,446 | −4,095 | 4.48% | $ 81.482M |
| CAREDX INC | CDNA 14167L103 | Equity | 906,349 | −13,117 | 3.71% | $ 67.577M |
| BEAM THERAPEUTICS INC | BEAM 07373V105 | Equity | 3,173,277 | −45,929 | 3.60% | $ 65.528M |
| SCHRODINGER INC | SDGR 80810D103 | Equity | 2,429,434 | −35,165 | 3.43% | $ 62.339M |
| ADAPTIVE BIOTECHNOLOGIES | ADPT 00650F109 | Equity | 1,974,865 | −28,587 | 3.09% | $ 56.264M |
| COMPASS PATHWAYS PLC | CMPS 20451W101 | Equity | 5,902,847 | −85,449 | 2.59% | $ 47.105M |
| VERACYTE INC | VCYT 92337F107 | Equity | 1,853,663 | −26,832 | 2.47% | $ 44.914M |
| RECURSION PHARMACEUTICALS-A | RXRX 75629V104 | Equity | 16,490,709 | −238,719 | 2.46% | $ 44.855M |
| NURIX THERAPEUTICS INC | NRIX 67080M103 | Equity | 2,790,715 | −40,391 | 2.18% | $ 39.74M |
| PRIME MEDICINE INC | PRME 74168J101 | Equity | 10,107,354 | −146,315 | 2.13% | $ 38.812M |
| ALAMAR BIOSCIENCES INC | ALMR 010911105 | Equity | 1,207,894 | −17,485 | 2.03% | $ 37.01M |
| INTELLIA THERAPEUTICS INC | NTLA 45826J105 | Equity | 3,497,291 | 0 | 1.88% | $ 34.204M |
| BUTTERFLY NETWORK INC | BFLY 124155102 | Equity | 5,308,710 | −76,843 | 1.68% | $ 30.525M |
| GENEDX HOLDINGS CORP | WGS 81663L200 | Equity | 622,315 | −9,009 | 1.62% | $ 29.429M |
| IONIS PHARMACEUTICALS INC | IONS 462222100 | Equity | 943,418 | −13,650 | 1.40% | $ 25.435M |
| ARCTURUS THERAPEUTICS HOLDIN | ARCT UQ 03969T109 | Equity | 3,174,891 | −45,955 | 1.39% | $ 25.304M |
| SCRIBE THERAPEUTICS INC | SCTX 811033109 | Equity | 1,597,118 | −2,771 | 1.38% | $ 25.187M |
| IAMBIC THERAPEUTICS INC | IAM 45076A101 | Equity | 1,748,162 | −25,298 | 1.37% | $ 24.859M |
| PACIFIC BIOSCIENCES OF CALIF | PACB 69404D108 | Equity | 12,542,409 | 0 | 1.25% | $ 22.827M |
| 908 DEVICES INC | MASS 65443P102 | Equity | 2,120,183 | −30,693 | 1.09% | $ 19.909M |
| FREENOME INC | FRNM 35661P100 | Equity | 1,851,391 | −26,793 | 1.00% | $ 18.181M |
| GENERATE BIOMEDICINES INC | GENB 370920100 | Equity | 1,700,605 | −24,609 | 0.92% | $ 16.734M |
| CERUS CORP | CERS 157085101 | Equity | 8,308,352 | 0 | 0.87% | $ 15.786M |
| KYMERA THERAPEUTICS INC | KYMR 501575104 | Equity | 127,214 | −1,833 | 0.85% | $ 15.459M |
| QUANTUM-SI INC | QSI 74765K105 | Equity | 7,523,110 | −108,901 | 0.42% | $ 7.598M |
|
GOLDMAN FS TRSY OBLIG INST 468
|
X9USDGSFT | Money market | 5,057,760 | +3,086,623 | 0.28% | $ 5.058M |
Trades Nov 17, 2026 to Nov 18, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| 10X GENOMICS INC-CLASS A | TXG | Sold | 2,626,038 | 2,480,914 | −145,124 | $ -8.17M |
| TEMPUS AI INC-CL A | TEM | Sold | 2,801,927 | 2,761,952 | −39,975 | $ -2.536M |
| GUARDANT HEALTH INC | GH | Sold | 661,210 | 651,785 | −9,425 | $ -1.35M |
| ELI LILLY & CO | LLY | Sold | 65,677 | 64,741 | −936 | $ -1.325M |
| TWIST BIOSCIENCE CORP | TWST | Bought | 1,370,221 | 1,381,558 | +11,337 | $ 1.27M |
| ILLUMINA INC | ILMN | Sold | 425,567 | 419,496 | −6,071 | $ -1.23M |
| ABSCI CORP | ABSI | Sold | 11,040,782 | 10,883,235 | −157,547 | $ -1.194M |
| NATERA INC | NTRA | Sold | 287,541 | 283,446 | −4,095 | $ -1.177M |
| CAREDX INC | CDNA | Sold | 919,466 | 906,349 | −13,117 | $ -978.004K |
| BEAM THERAPEUTICS INC | BEAM | Sold | 3,219,206 | 3,173,277 | −45,929 | $ -948.434K |
| SCHRODINGER INC | SDGR | Sold | 2,464,599 | 2,429,434 | −35,165 | $ -902.334K |
| ADAPTIVE BIOTECHNOLOGIES | ADPT | Sold | 2,003,452 | 1,974,865 | −28,587 | $ -814.444K |
| COMPASS PATHWAYS PLC | CMPS | Sold | 5,988,296 | 5,902,847 | −85,449 | $ -681.883K |
| VERACYTE INC | VCYT | Sold | 1,880,495 | 1,853,663 | −26,832 | $ -650.139K |
| RECURSION PHARMACEUTICALS-A | RXRX | Sold | 16,729,428 | 16,490,709 | −238,719 | $ -649.316K |
| NURIX THERAPEUTICS INC | NRIX | Sold | 2,831,106 | 2,790,715 | −40,391 | $ -575.168K |
| PRIME MEDICINE INC | PRME | Sold | 10,253,669 | 10,107,354 | −146,315 | $ -561.85K |
| ALAMAR BIOSCIENCES INC | ALMR | Sold | 1,225,379 | 1,207,894 | −17,485 | $ -535.74K |
| BUTTERFLY NETWORK INC | BFLY | Sold | 5,385,553 | 5,308,710 | −76,843 | $ -441.847K |
| GENEDX HOLDINGS CORP | WGS | Sold | 631,324 | 622,315 | −9,009 | $ -426.036K |
| IONIS PHARMACEUTICALS INC | IONS | Sold | 957,068 | 943,418 | −13,650 | $ -368.004K |
| ARCTURUS THERAPEUTICS HOLDIN | ARCT UQ | Sold | 3,220,846 | 3,174,891 | −45,955 | $ -366.261K |
| IAMBIC THERAPEUTICS INC | IAM | Sold | 1,773,460 | 1,748,162 | −25,298 | $ -359.738K |
| 908 DEVICES INC | MASS | Sold | 2,150,876 | 2,120,183 | −30,693 | $ -288.207K |
| FREENOME INC | FRNM | Sold | 1,878,184 | 1,851,391 | −26,793 | $ -263.107K |
| GENERATE BIOMEDICINES INC | GENB | Sold | 1,725,214 | 1,700,605 | −24,609 | $ -242.153K |
| KYMERA THERAPEUTICS INC | KYMR | Sold | 129,047 | 127,214 | −1,833 | $ -222.746K |
| QUANTUM-SI INC | QSI | Sold | 7,632,011 | 7,523,110 | −108,901 | $ -109.99K |
| SCRIBE THERAPEUTICS INC | SCTX | Sold | 1,599,889 | 1,597,118 | −2,771 | $ -43.699K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up